Cargando…

Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies

Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytosol of the target cell, which is required to mediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs, Hendrik, Niesler, Nicole, Trautner, Alexandra, Sama, Simko, Jerz, Gerold, Panjideh, Hossein, Weng, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489800/
https://www.ncbi.nlm.nih.gov/pubmed/28536357
http://dx.doi.org/10.3390/biomedicines5020014
_version_ 1783246862626586624
author Fuchs, Hendrik
Niesler, Nicole
Trautner, Alexandra
Sama, Simko
Jerz, Gerold
Panjideh, Hossein
Weng, Alexander
author_facet Fuchs, Hendrik
Niesler, Nicole
Trautner, Alexandra
Sama, Simko
Jerz, Gerold
Panjideh, Hossein
Weng, Alexander
author_sort Fuchs, Hendrik
collection PubMed
description Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytosol of the target cell, which is required to mediate the fatal effect. Target receptor bound and internalized toxins are mostly either recycled back to the cell surface or lysosomally degraded. This might explain why no antibody-targeted protein toxin has been approved for tumor therapeutic applications by the authorities to date although more than 500 targeted toxins have been developed within the last decades. To overcome the problem of insufficient endosomal escape, a number of strategies that make use of diverse chemicals, cell-penetrating or fusogenic peptides, and light-induced techniques were designed to weaken the membrane integrity of endosomes. This review focuses on glycosylated triterpenoids as endosomal escape enhancers and throws light on their structure, the mechanism of action, and on their efficacy in cell culture and animal models. Obstacles, challenges, opportunities, and future prospects are discussed.
format Online
Article
Text
id pubmed-5489800
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54898002017-06-30 Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies Fuchs, Hendrik Niesler, Nicole Trautner, Alexandra Sama, Simko Jerz, Gerold Panjideh, Hossein Weng, Alexander Biomedicines Review Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytosol of the target cell, which is required to mediate the fatal effect. Target receptor bound and internalized toxins are mostly either recycled back to the cell surface or lysosomally degraded. This might explain why no antibody-targeted protein toxin has been approved for tumor therapeutic applications by the authorities to date although more than 500 targeted toxins have been developed within the last decades. To overcome the problem of insufficient endosomal escape, a number of strategies that make use of diverse chemicals, cell-penetrating or fusogenic peptides, and light-induced techniques were designed to weaken the membrane integrity of endosomes. This review focuses on glycosylated triterpenoids as endosomal escape enhancers and throws light on their structure, the mechanism of action, and on their efficacy in cell culture and animal models. Obstacles, challenges, opportunities, and future prospects are discussed. MDPI 2017-03-29 /pmc/articles/PMC5489800/ /pubmed/28536357 http://dx.doi.org/10.3390/biomedicines5020014 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fuchs, Hendrik
Niesler, Nicole
Trautner, Alexandra
Sama, Simko
Jerz, Gerold
Panjideh, Hossein
Weng, Alexander
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
title Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
title_full Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
title_fullStr Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
title_full_unstemmed Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
title_short Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
title_sort glycosylated triterpenoids as endosomal escape enhancers in targeted tumor therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489800/
https://www.ncbi.nlm.nih.gov/pubmed/28536357
http://dx.doi.org/10.3390/biomedicines5020014
work_keys_str_mv AT fuchshendrik glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies
AT nieslernicole glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies
AT trautneralexandra glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies
AT samasimko glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies
AT jerzgerold glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies
AT panjidehhossein glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies
AT wengalexander glycosylatedtriterpenoidsasendosomalescapeenhancersintargetedtumortherapies